Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children's oncology group ARST0332 trial.

Journal of the National Cancer Institute·2026
Same author

Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients.

Journal of surgical oncology·2026
Same author

Multiplex Imaging Mass Cytometry Reveals Prognostic Immunosuppressive Subpopulations and Macrophage-Driven Metastasis in Osteosarcoma.

Cancers·2025
Same author

Should We Stop Assessing Intraoperative Frozen Section Marrow Margins During Ewing Sarcoma Resection?

Clinical orthopaedics and related research·2025
Same author

What Is the Prevalence and Fate of Myxoid Soft-Tissue Tumors With an Indeterminate Diagnosis Prior to Resection?

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2025
Same author

Distinguishing benign and malignant myxoid soft tissue tumors: Performance of radiomics vs. radiologists.

PloS one·2025

Related Experiment Video

Updated: May 22, 2026

Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

Nuclear p63 expression in osteoblastic tumors.

Michael E Kallen1, Melinda E Sanders, Adriana L Gonzalez

  • 1Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Medical Center North, C-3322, 1161 21st Ave. South, Nashville, TN 37232, USA.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|May 25, 2012
PubMed
Summary

p63 protein is found in most osteoblastomas and some osteosarcomas, limiting its use as a diagnostic marker for bone tumors. This protein does not reliably indicate osteoblastic differentiation in skeletal sarcomas.

More Related Videos

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
07:00

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Related Experiment Videos

Last Updated: May 22, 2026

Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
07:00

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Area of Science:

  • Oncology
  • Bone Tumors
  • Immunohistochemistry

Background:

  • p63 protein expression is noted in osteoblast-precursor cells of giant cell tumors of the bone.
  • Limited studies have explored p63 expression in osteoblastic tumors.
  • Osteosarcoma and osteoblastoma are bone tumors with osteoblastic differentiation.

Purpose of the Study:

  • To investigate p63 as a potential marker for osteoblastic differentiation in osteosarcomas.
  • To evaluate p63 as a differential diagnostic marker between osteoblastoma and osteosarcoma.

Main Methods:

  • Immunohistochemical staining for p63 was performed on tissue microarrays and whole sections.
  • Samples included 71 chemotherapy-naive osteosarcoma biopsy samples, 21 whole osteosarcoma sections, and 8 osteoblastomas.

Main Results:

  • Nuclear p63 was detected in 7 of 8 osteoblastomas, primarily in stromal cells of immature areas.
  • p63 was positive in 10% of osteosarcoma biopsy samples and 33% of whole osteosarcoma sections.
  • p63 expression was observed in both benign osteoblastomas and malignant osteosarcomas.

Conclusions:

  • p63 expression in both osteoblastoma and osteosarcoma limits its utility in differentiating between these bone tumors.
  • p63 is not a reliable marker for osteoblastic differentiation in skeletal sarcomas due to its low prevalence in osteosarcoma.